Claims for Patent: 4,393,133

✉ Email this page to a colleague

Summary for Patent: 4,393,133

Title:	Human hepatoma derived cell line, process for preparation thereof, and uses therefor
Abstract:	Human hepatoma cell lines, useful for metabolic studies such as screening potential carcinogens and mutagens, for cultivation of viruses, and for preparation of vaccines is obtained by culturing human hepatocarcinoma or hepatoblastoma on lethally irradiated cell feeder layers in the presence of a culture medium.
Inventor(s):	Knowles; Barbara B. (West Chester, PA), Aden; David P. (Philadelphia, PA)
Assignee:	The Wistar Institute of Anatomy and Biology (Philadelphia, PA)
Application Number:	06/158,685
Patent Claims:	1. A process for assessing the metabolic conversion of chemicals and drugs considered to be potential carcinogens and mutagens, which comprises: (a) maintaining a culture of a human hepatic cell line selected from the group consisting of the cell lines designated Hep 3B and Hep G2 in a nutrient medium, (b) exposing said cell line to the chemical or drug to be tested, (c) analyzing said culture for the presence of metabolites of said chemical or drug, and (d) introducing said metabolites to cultures of other mammalian cells to determine their mutagenic capabilities. 2. The process according to claim 1 in which said cell line comprises Hep G2. 3. The process according to claim 1 in which said cell line comprises Hep 3B. 4. A process for isolation of hepatitis B virus surface antigen for use as a vaccine which comprises: (a) maintaining a human hepatic cell line, designated Hep 3B, which contains the hepatitis B virus genome in nutrient culture medium, (b) recovering the supernatant fluid from said culture, and (c) purifying the hepatitis B virus surface antigen in said supernatant fluid for use as a vaccine. 5. A process for isolation of human plasma proteins which comprises: (a) maintaining a human hepatic cell line which synthesizes plasma proteins selected from the group consisting of the cell lines designated Hep 3B and Hep G2 in a nutrient culture medium, (b) recovering the supernatant fluid from said culture, and (c) separating plasma proteins from said supernatant fluid, and purifying said plasma proteins. 6. The process according to claim 5 in which said cell line comprises Hep G2. 7. The process according to claim 5 in which said cell line comprises Hep 3B. 8. The cell line having the identifying characteristics of Hep 3B. 9. The cell line having the identifying characteristics of Hep G2.

Details for Patent 4,393,133

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAPLAS	pooled plasma (human), solvent/detergent treated	For Injection	125416	January 17, 2013	⤷ Subscribe	2040-01-29
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.